Verastem (VSTM) Oncology announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the securities to be sold in the offering are to be sold by Verastem Oncology. Verastem Oncology intends to use the net proceeds from the proposed public offering to fund commercial activities for AVMAPKI FAKZYNJA CO-PACK that has been approved by the FDA to treat KRAS-mutated recurrent Low-Grade Serous Ovarian Cancer, continued clinical research and development of product candidates including the VS-7375 oral KRAS G12D (ON/OFF) inhibitor program, and for working capital and other general corporate purposes. Jefferies, Guggenheim Securities and Cantor are acting as joint book-running managers for the proposed offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem’s Strong Commercial Performance and Growth Potential Reinforce Buy Rating
- Verastem Oncology Reports Strong Q3 2025 Results
- Verastem Inc’s Earnings Call: Strong Launch and Financial Outlook
- Verastem’s Strong Financial Performance and Strategic Developments Justify Buy Rating Despite Minor Concerns
- Verastem weakness appears overdone, says Mizuho